Active transport across the human placenta: impact on drug efficacy and toxicity

Bibliography

• BRIGGS GG, FREEMAN RK, YAFFE SJ: Drugs in Pregnancy and Lactation. Lippincott Williams & Wilkins, Philadelphia, US (2005).
   Google Scholar
• CUNNINGHAM EA, LEVENO KJ: Williams Obstetrics. McGraw-Hill, NewYork, US (2002).
   Google Scholar
• SHIVERICK KT, SLIKKER W, ROGERSON SJ, MILLER RK: Drugs and the placenta a workshop report. Placenta (2003) 17(Suppl. A):S55-S59.
   Google Scholar
• THADANI PV, STRAUSS JF, DEY SK etal.: National Institute on Drug Abuse Conference report on placental proteins, drug transport, and fetal development. Am. J. Obstet. Gynecol. (2004) 191(6):1858-1862.
   PubMed Web of Science ®Google Scholar
• ANDRADE SE, GURWITZ JH, DAVISRL etal.: Prescription drug use in pregnancy. Am. J. Obstet. Gynecol. (2004) 191(2):398-407.
   PubMed Web of Science ®Google Scholar
• OLESEN C, SORENSEN HT, DEJONG-VAN DEN BERG L, OLSENJ, STEFFENSEN FH: Prescribing during pregnancy and lactation with reference to the Swedish classification system. A population-based study among Danish women. The Euromap Group. Acta Obstet. Gynecol. Scand. (1999) 78(8):686-692.
   PubMed Web of Science ®Google Scholar
• LANKAS GR, WISE LD, CARTWRIGHTME, PIPPERT T, UMBENHAUER DR: Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod. Toxicol. (1998) 12(4):457-463.
   PubMed Web of Science ®Google Scholar
• SYME MR, PAXTON JW, KEELAN JA: Drug transfer and metabolism by the human placenta. Clin. Pharmacokinet. (2004) 43(8):487-514.
   PubMed Web of Science ®Google Scholar
• GANAPATHY V, PRASAD PD, GANAPATHY ME, LEIBACH FH: Placental transporters relevant to drug distribution across the maternalfetal interface. J. Pharmacol. Exp. Ther. (2000) 294(2):413-420.
   PubMed Web of Science ®Google Scholar
• HITZL M, SCHAEFFELER E, HOCHERB etal.: Variable expression of P-glycoprotein in the human placenta and its association with mutations of the multidrug resistance 1 gene (MDR1, ABCB1). Pharmacogenetics (2004) 14(5):309-318.
   PubMedGoogle Scholar
• GARLAND M: Pharmacology of drug transfer across the placenta. Obstet. Gynecol. Clin. North Am. (1998) 25(1):21-42.
   PubMed Web of Science ®Google Scholar
• COLLIER AC, TINGLE MD, PAXTONJW, MITCHELL MD, KEELAN JA: Metabolizing enzyme localization and activities in the first trimester human placenta: the effect of maternal and gestational age, smoking and alcohol consumption. Hum. Reprod. (2002) 17(10):2564-2572.
   PubMed Web of Science ®Google Scholar
• COLLIER AC, GANLEY NA, TINGLEMD etal.: UDP-glucuronosyltransferase activity, expression and cellular localization in human placenta at term. Biochem. Pharmacol. (2002) 63(3):409-419.
   PubMed Web of Science ®Google Scholar
• ST-PIERRE MV, UGELE B, GAMBLINGL, SHIVERICK KT: Mechanisms of drug transfer across the human placenta a workshop report. Placenta (2002) 23(A):S159-S164.
   PubMed Web of Science ®Google Scholar
• YOUNG AM, ALLEN CE, AUDUS KL: Efflux transporters of the human placenta. Adv. Drug Deliv. Rev. (2003) 55:125-132.
   PubMed Web of Science ®Google Scholar
• MATHIAS AA, HITTI J, UNADKAT JD: P-glycoprotein and breast cancer-resistance protein expression in human placentae of various gestational ages. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2005) 289(4):R963-R969
   PubMed Web of Science ®Google Scholar
• HIGGINS CF, HILES I, SALMOND G etal.: A family of related ATP-binding subunits coupled to many distinct biological processes in bacteria. Nature (1986) 323:448-450.
   PubMed Web of Science ®Google Scholar
• HYDE SC, EMSLEY P, HARTSHORNMF etal.: Structural model of ATP-binding proteins associated with cystic fibrosis, multi-drug resistance and bacterial transport. Nature (1990) 346:362-365.
   PubMed Web of Science ®Google Scholar
• OZVERGY C, LITMAN T, SZAKACS G etal.: Functional characterization of the human multi-drug transporter, ABCG2, expressed in insect cells. Biochem. Biophys. Res. Commun. (2001) 285:111-117.
   PubMed Web of Science ®Google Scholar
• LITMAN T, DRULEY TE, STEIN WD, BATES SE: From MDR to MXR: new understanding of multi-drug resistance systems, their properties and clinical significance. Cell. Mol. Life Sci. (2001) 58(7):931-959.
   PubMed Web of Science ®Google Scholar
• SHAPIRO AB, LING V: Transport of LDS-751 from the cytoplasmic leaflet of the plasma membrane by the rhodamine-123-selective site of P-glycoprotein. Eur. J. Biochem. (1998) 254(1):181-188.
   PubMedGoogle Scholar
• BODO A, BAKOS E, SZERI F, VARADIA, SARKADI B: The role of multidrug transporters in drug availability, metabolism and toxicity. Toxicol. Lett. (2003) 140-141:133-143.
   PubMed Web of Science ®Google Scholar
• USHIGOME F, TAKANAGA H, MATSUO H etal.: Human placental transport of vinblastine, vincristine, digoxin and progesterone: contribution of P-glycoprotein. Eur. J. Pharmacol. (2000) 408(1):1-10.
   PubMed Web of Science ®Google Scholar
• SMIT JW, HUISMAN MT, VANTELLINGEN O, WILTSHIRE HR, SCHINKEL AH: Absence or pharmacological blocking of placental P-glycoprotein profoundly increases fetal drug exposure. J. Clin. Invest. (1999) 104(10):1441-1447.
   PubMed Web of Science ®Google Scholar
• MACFARLAND A, ABRAMOVICH DR, EWEN SW, PEARSON CK: Stage-specific distribution of P-glycoprotein in first-trimester and full-term human placenta. Histochem. J. (1994) 26(5):417-423.
   PubMedGoogle Scholar
• USHIGOME F, KOYABU N, SATOH S etal.: Kinetic analysis of P-glycoprotein-mediated transport by using normal human placental brush-border membrane vesicles. Pharmaceut. Res. (2003) 20(1):38-44.
   PubMed Web of Science ®Google Scholar
• NAGASHIGE M, USHIGOME F, KOYABU N etal.: Basal membrane localisation of MRP1 in human placental trophoblast. Placenta (2003) 24:951-958.
   PubMed Web of Science ®Google Scholar
• SMITH AJ, VAN HELVOORT A, VANMEER G etal.: MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping. J. Biol. Chem. (2000) 275(31):23530-23539.
   PubMed Web of Science ®Google Scholar
• SMITH AJ, TIMMERMANS-HEREIJGERS JL, ROELOFSEN B etal.: The human MDR3 P-glycoprotein promotes translocation of phosphatidylcholine through the plasma membrane of fibroblasts from transgenic mice. FEBS Lett. (1994) 354(3):263-266.
   PubMed Web of Science ®Google Scholar
• DIXON PH, WEERASEKERA N, LINTON K etal.: Heterozygous MDR3 missense mutation associated with intrahepatic cholestasis of pregnancy: evidence for a defect in protein trafficking. Hum. Molec. Genet. (2000) 9(8):1209-1217.
   PubMed Web of Science ®Google Scholar
• BORST P, ZELCER N, VANHELVOORT A: ABC transporters in lipid transport. Biochim. Biophys. Acta (2000) 1486(1):128-144.
   PubMed Web of Science ®Google Scholar
• PATEL P, WEERASEKERA N, HITCHINS M etal.: Semi-quantitative expression analysis of MDR3, FIC1, BSEP, OATP-A, OATP-C,OATP-D, OATP-E and NTCP gene transcripts in first and third trimester human placenta. Placenta (2003) 24(1):39-44.
   PubMed Web of Science ®Google Scholar
• HAIMEUR A, CONSEIL G, DEELEYRG, COLE SP: The MRP-related and BCRP/ABCG2 multi-drug resistance proteins: biology, substrate specificity and regulation. Curr. Drug Metab. (2004) 5(1):21-53.
   PubMed Web of Science ®Google Scholar
• PASCOLO L, FERNETTI C, GARCIA-MEDIAVILLA MV, OSTROWJD, TIRIBELLI C: Mechanisms for the transport of unconjugated bilirubin in human trophoblastic BeWo cells. FEBS Lett. (2001) 495(1-2):94-99.
   PubMed Web of Science ®Google Scholar
• PASCOLO L, FERNETTI C, PIRULLI D etal.: Effect of maturation on RNA transcription and protein expression of four MRP genes in human placenta and BeWo cells. Biochem. Biophys. Res. Commun. (2003) 303(1):259-265.
   PubMed Web of Science ®Google Scholar
• HIPFNER DR, DEELEY RG, COLE SP: Structural, mechanistic and clinical aspects of MRP1. Biochim. Biophys. Acta (1999) 1461(2):359-376.
   PubMed Web of Science ®Google Scholar
• ST-PIERRE MV, SERRANO MA, MACIAS RI etal.: Expression of members of the multidrug resistance family in human term placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2000) 279(4):495-503.
   Google Scholar
• CHAN L, LOWES S, HIRST BH: The ABCs drug transport in intestine and liver: efflux proteins limiting drug absorbtion and bioavailability. Eur. J. Pharmaceut. Sci. (2004) 21:25-51.
   PubMed Web of Science ®Google Scholar
• KEPPLER D, LEIER I, JEDLITSCHKYG, KONIG J: ATP-dependent transport of glutathione S-conjugates by the multidrug resistance protein MRP1 and its apical isoform MRP2. Chem. Biol. Interact. (1998) 111-112:153-161.
   PubMed Web of Science ®Google Scholar
• MARIN JJ, MACIAS RI, BRIZ O, PEREZMJ, SERRANO MA: Molecular bases of the excretion of fetal bile acids and pigments through the fetal liver-placenta-maternal liver pathway. Ann. Hepatol. (2005) 4(2):70-76.
   PubMedGoogle Scholar
• BELINSKY MG, KRUH GD: MOAT-E (ARA) is a full-length MRP/cMOAT subfamily transporter expressed in kidney and liver. Br. J. Cancer (1999) 80(9):1342-1349.
   PubMed Web of Science ®Google Scholar
• HIROHASHI T, SUZUKI H, SUGIYAMA Y: Characterization of the transport properties of cloned rat multi-drug resistance-associated protein 3 (MRP3). J. Biol. Chem. (1999) 274(21):15181-15185.
   PubMed Web of Science ®Google Scholar
• ST-PIERRE MV, SERRANO MA, MACIAS RI etal.: Expression of members of the multidrug resistance protein family in human term placenta. Am. J. Physiol. Regul. Integr. Comp. Physiol. (2000) 279(4):R1495-R1503.
   PubMed Web of Science ®Google Scholar
• REID G, WIELINGA P, ZELCER N etal.: The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal anti-inflammatory drugs. Proc. Natl. Acad. Sci. USA (2003) 100(16):9244-9249.
   PubMed Web of Science ®Google Scholar
• LEGGAS M, ADACHI M, SCHEFFERGL etal.: Mrp4 confers resistance to topotecan and protects the brain from chemotherapy. Mol. Cell. Biol. (2004) 24(17):7612-7621.
   PubMed Web of Science ®Google Scholar
• VAN AUBEL RA, SMEETS PH, VANDEN HEUVEL JJ, RUSSEL FG: Human organic anion transporter MRP4 (ABCC4) is an efflux pump for the purine end metabolite urate with multiple allosteric substrate binding sites. Am. J. Physiol. Renal Physiol (2005) 288(2):F327-F333.
   PubMed Web of Science ®Google Scholar
• LANGMANN T, MAUERER R, ZAHN A etal.: Real time RT-PCR expression profiling of the complete human ATP-binding cassete superfamily in various tissues. Clin. Chem. (2003) 49:230-238.
   PubMed Web of Science ®Google Scholar
• WIELINGA PR, VAN DER HEIJDEN I, REID G etal.: Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J. Biol. Chem. (2003) 278(20):17664-17671.
   PubMed Web of Science ®Google Scholar
• BELINSKY MG, BAIN LJ, BALSARA BB, TESTA JR, KRUH GD: Characterization of MOAT-C and MOAT-D, new members of the MRP/cMOAT subfamily of transporter proteins. J. Natl. Cancer Inst. (1998) 90(22):1735-1741.
   PubMed Web of Science ®Google Scholar
• JEDLITSCHKY G, BURCHELL B, KEPPLER D: The multi-drug resistance protein 5 functions as an ATP-dependent export pump for cyclic nucleotides. J. Biol. Chem. (2000) 275(39):30069-30074.
   PubMed Web of Science ®Google Scholar
• MEYER ZU SCHWABEDISSEN HE, GRUBE M, HEYDRICH B etal.: Expression, localization, and function of MRP5 (ABCC5), a transporter for cyclic nucleotides, in human placenta and cultured human trophoblasts: effects of gestational age and cellular. Differentiation (2005):39-48.
   Google Scholar
• CHEN Z, HOPPER E, BELINSKY MG etal.: Characterization of the transport properties of human multi-drug resistance protein 7. Mol. Pharmacol. (2003) 63(2):351-358.
   PubMed Web of Science ®Google Scholar
• BERA TK, LEE S, SALVATORE G, LEEB, PASTAN I: MRP8, a new member of ABC transporter superfamily, identified by EST database mining and gene prediction program, is highly expressed in breast cancer. Mol. Med. (2001) 7(8):509-516.
   PubMed Web of Science ®Google Scholar
• CHEN ZS, GUO Y, BELINSKY MG, KOTOVA E, KRUH GD: Transport of bile acids, sulfated steroids, estradiol 17--d-glucuronide, and leukotriene C4 by human multidrug resistance protein 8 (ABCC11). Mol. Pharmacol. (2005) 67(2):545-557.
   PubMed Web of Science ®Google Scholar
• YABUUCHI H, TAKAYANAGI S, YOSHINAGA K etal.: ABCC13, an unusual truncated ABC transporter, is highly expressed in fetal human liver. Biochem. Biophys. Res. Commun. (2002) 299(3):410-417.
   PubMed Web of Science ®Google Scholar
• ALLIKMETS R, LMS, HUTCHINSONA, ROMANO-SPICA V, DEAN M: A human placenta-specific ATP-binding cassete gene on chromosome 4q22 that is involved in multi-drug resistance. Cancer Res. (1998) 58:5337-5339.
   PubMed Web of Science ®Google Scholar
• LANGMANN T, MAUERER R, ZAHN A etal.: Real-time reverse transcription-PCR expression profiling of the complete human ATP-binding cassette transporter superfamily in various tissues. Clin. Chem. (2003) 49(2):230-238.
   PubMed Web of Science ®Google Scholar
• LITMAN T, JENSEN U, HANSEN A etal.: Use of peptide antibodies to probe for the mitoxantrone resistance-associated protein. Biochem. Biophys. Res. Commun. (2002) 1565(1):6-16.
   Google Scholar
• SARKADI B, OZVEGY-LACZKA C, NEMET K, VARADI A: ABCG2 a transporter for all seasons. FEBS Lett. (2004) 567(1):116-120.
   PubMed Web of Science ®Google Scholar
• QADIR M, OLOUGHLIN KL, FRICKESM etal.: Cyclosporin A is a broad-spectrum multi-drug resistance modulator. Clin. Cancer Res. (2005) 11(6):2320-2326.
   PubMed Web of Science ®Google Scholar
• JONKER JW, SMIT JW, BRINKHUIS M etal.: Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. (2000) 92(20):1651-1656.
   PubMed Web of Science ®Google Scholar
• JONKER JW, MERINO G, MUSTERS S etal.: The breast cancer resistance protein BCRP (ABCG2) concentrates drugs and carcinogenic xenotoxins into milk. Nat. Med. (2005) 11(2):127-129.
   PubMed Web of Science ®Google Scholar
• MERINO G, JONKER JW, WAGENAARE, VANHERWAARDENAE, SCHINKELAH: The breast cancer-resistance protein (BCRP/ABCG2) affects pharmacokinetics, hepatobiliary excretion, and milk secretion of the antibiotic nitrofurantoin. Mol. Pharmacol. (2005) 67(5):1758-1764.
   PubMed Web of Science ®Google Scholar
• SWEET DH: Organic anion transporter (Slc22a) family members as mediators of toxicity. Toxicol. Appl. Pharmacol. (2005) 204(3):198-215.
   PubMed Web of Science ®Google Scholar
• MIYAZAKI H, SEKINE T, ENDOU H: The multispecific organic anion transporter family: properties and pharmacological significance. Trends Pharmacol. Sci. (2004) 25(12):654-662.
   PubMed Web of Science ®Google Scholar
• HOSOYAMADA M, SEKINE T, KANAIY, ENDOU H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol. (1999) 276(1Pt2):F122-F128.
   PubMed Web of Science ®Google Scholar
• CHA SH, SEKINE T, KUSUHARA H etal.: Molecular cloning and characterization of multispecific organic anion transporter 4 expressed in the placenta. J. Biol. Chem. (2000) 275(6):4507-4512.
   PubMed Web of Science ®Google Scholar
• UGELE B, ST-PIERRE MV, PIHUSCHM, BAHN A, HANTSCHMANN P: Characterization and identification of steroid sulfate transporters of human placenta. Am. J. Physiol. Endocrinol. Metab. (2003) 284(2):E390-E398.
   PubMed Web of Science ®Google Scholar
• BLACK S, KADYROV M, KAUFMANNP etal.: Syncytial fusion of human trophoblast depends on caspase 8. Cell Death Differ. (2004) 11(1):90-98.
   PubMed Web of Science ®Google Scholar
• MIKKAICHI T, SUZUKI T, TANEMOTO M, ITO S, ABE T: The organic anion transporter (OATP) family. Drug Metab. Pharmacokinet. (2004) 19(3):171-179.
   PubMedGoogle Scholar
• SATO K, SUGAWARA J, SATO T etal.: Expression of organic anion transporting polypeptide E (OATP-E) in human placenta. Placenta (2003) 24(2-3):144-148.
   PubMed Web of Science ®Google Scholar
• ST-PIERRE MV, HAGENBUCH B, UGELE B, MEIER PJ, STALLMACH T: Characterization of an organic anion-transporting polypeptide (OATP-B) in human placenta. J Clin. Endocrinol. Metab. (2002) 87(4):1856-1863.
   PubMed Web of Science ®Google Scholar
• BRIZ O, SERRANO MA, MACIAS RI, GONZALEZ-GALLEGO J, MARIN JJ: Role of organic anion-transporting polypeptides, OATP-A, OATP-C and OATP-8, in the human placenta-maternal liver tandem excretory pathway for foetal bilirubin. Biochem. J. (2003) 371(3):897-905.
   PubMed Web of Science ®Google Scholar
• GANAPTHY V, ZHUANG L, DEVOELD, PRASAD PD: Expression of OCTN1 in placental brush border membrane and its iunteraction with antidepressants. J. Soc. Gynecol. Invest. (2005) 12(2):180A.
   Google Scholar
• KITANO T, IIZASA H, HWANG IW etal.: Conditionally immortalized syncytiotrophoblast cell lines as new tools for study of the bloodplacenta barrier. Biol. Pharm. Bull. (2004) 27(6):753-759.
   PubMed Web of Science ®Google Scholar
• GRUBE M, SCHWABEDISSEN HM, DRABER K etal.: Expression, localization, and function of the carnitine transporter octn2 (slc22a5) in human placenta. Drug Metab. Dispos. (2005) 33(1):31-37.
   PubMed Web of Science ®Google Scholar
• SHEARMAN LP, MEYER JS: Cocaine up-regulates norepinephrine transporter binding in the rat placenta. Eur. J. Pharmacol. (1999) 386(1):1-6.
   PubMed Web of Science ®Google Scholar
• BALDWIN SA, YAO SY, HYDE RJ etal.: Functional characterization of novel human and mouse equilibrative nucleoside transporters (hENT3 and mENT3) located in intracellular membranes. J. Biol. Chem. (2005) 280(16):15880-15887.
   PubMed Web of Science ®Google Scholar
• BARROS LF, YUDILEVICH DL, JARVISSM etal.: Immunolocalisation of nucleoside transporters in human placental trophoblast and endothelial cells: evidence for multiple transporter isoforms. Pflugers Arch. (1995) 429(3):394-399.
   PubMed Web of Science ®Google Scholar
• GRIFFITHS M, YAO SY, ABIDI F etal.: Molecular cloning and characterization of a nitrobenzylthioinosine-insensitive (ei) equilibrative nucleoside transporter from human placenta. Biochem. J. (1997) 328(3):739-743.
   PubMed Web of Science ®Google Scholar
• SETTLE P, MYNETT K, SPEAKE P etal.: Polarized lactate transporter activity and expression in the syncytiotrophoblast of the term human placenta. Placenta (2004) 25(6):496-504.
   PubMed Web of Science ®Google Scholar
• GWYN K: Children exposed to chemotherapy in utero. J. Natl. Cancer Inst. Monogr. (2005) 34:69-71.
   PubMedGoogle Scholar
• SMITH LH, DALRYMPLE JL, LEISEROWITZ GS, DANIELSEN B, GILBERT WM: Obstetrical deliveries associated with maternal malignancy in California. Am. J. Obstet. Gynecol. (2001) 184:1504-1511.
   PubMed Web of Science ®Google Scholar
• ANTONELLI NM, DOTTERS DJ, KATZVL, KULLER JA: Cancer in pregnancy a review of the literature. Obstet. Gynecol. Surv. (1996) 51:125-142.
   PubMedGoogle Scholar
• LESLIE KK: Chemotherapy and pregnancy. Clin. Obstet. Gynecol. (2002) 45(1):153-164.
   PubMed Web of Science ®Google Scholar
• SCHINKEL AH, JONKER JW: Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. (2003) 55(1):3-29.
   PubMed Web of Science ®Google Scholar
• EBERT U, LOFFLER H, KIRCH W: Cytotoxic therapy and pregnancy. Pharmacol. Ther. (1997) 74(2):207-220.
   PubMed Web of Science ®Google Scholar
• MATALON ST, ORNOY A, LISHNER M: Review of the potential effects of three commonly used antineoplastic and immunosuppressive drugs (cyclophosphamide, azathioprine, doxorubicin on the embryo and placenta. Reprod. Toxicol. (2004) 18(2):219-230.
   PubMed Web of Science ®Google Scholar
• SCHUURHUIS GJ, BROXTERMAN HJ, DE LANGE JH etal.: Early multi-drug resistance, defined by changes in intracellular doxorubicin distribution, independent of P-glycoprotein. Br. J. Cancer (1991) 64(5):857-861.
   PubMed Web of Science ®Google Scholar
• DRION N, LEMAIRE M, LEFAUCONNIER JM, SCHERRMANNJM: Role of P-glycoprotein in the bloodbrain transport of colchicine and vinblastine. J. Neurochem. (1996) 67:1688-1693.
   PubMed Web of Science ®Google Scholar
• KEMPER EM, VAN ZANDBERGEN AE, CLEYPOOL C etal.: Increased penetration of paclitaxel into the brain by inhibition of P-glycoprotein. Clin. Cancer Res. (2003) 9:2849-2855.
   PubMed Web of Science ®Google Scholar
• GROHARD P, AKBARALY JP, SAUX MC etal.: Transplacental passage of doxorubicin. J. Gynecol. Obstet. Biol. Reprod. (Paris) (1989) 18(5):595-600.
   PubMedGoogle Scholar
• ROBOZ J, GLEICHER N, WU K etal.: Does doxorubicin cross the placenta? Lancet (1979) 2(8156-8157):1382-1383.
   PubMed Web of Science ®Google Scholar
• KARP GI, VON OEYEN P, VALONE F etal.: Doxorubicin in pregnancy: possible transplacental passage. Cancer Treat. Rep. (1983) 67(9):773-777.
   PubMedGoogle Scholar
• DINCALCI M, BROGGINI M, BUSCAGLIA M, PARDI G: Transplacental passage of doxorubicin. Lancet (1983) 1(8314-5):75.
   PubMedGoogle Scholar
• EE PL, HE X, ROSS DD, BECK WT: Modulation of breast cancer-resistance protein (BCRP/ABCG2) gene expression using RNA interference. Mol. Cancer Ther. (2004) 3(12):1577-1583.
   PubMed Web of Science ®Google Scholar
• KRUIJTZER CM, BEIJNEN JH, ROSING H etal.: Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF-120918. J. Clin. Oncol. (2002) 20(13):2943-2950.
   PubMed Web of Science ®Google Scholar
• JONKER JW, SMIT JW, BRINKHUIS RF etal.: Role of breast cancer-resistance protein in the bioavailability and fetal penetration of topotecan. J. Natl. Cancer Inst. (2000) 92(20):1651-1656.
   PubMed Web of Science ®Google Scholar
• AVILES A, NERI N: Hematological malignancies and pregnancy: a final report of 84 children who received chemotherapy in utero. Clin. Lymphoma (2001) 2(3):173-177.
   PubMedGoogle Scholar
• ABBAS AE, LESTER SJ, CONNOLLY H: Pregnancy and the cardiovascular system. Int. J. Cardiol. (2005) 98(2):179-189.
   PubMed Web of Science ®Google Scholar
• MISHELL D, GOODWIN TM, BRENNER P: Management of Common Problems in Obstetrics and Gynecology (4thedition). Blackwell Publishing, NewYork, US (2002).
   Google Scholar
• AVILA WS, ROSSI EG, RAMIRES JA etal.: Pregnancy in patients with heart disease: experience with 1000 cases. Clin. Cardiol. (2003) 26(3):135-142.
   PubMed Web of Science ®Google Scholar
• SIU S, COLMAN JM: Cardiovascular problems and pregnancy: an approach to management. Cleveland Clin. J. Med. (2004) 71(12):977-985.
   PubMed Web of Science ®Google Scholar
• LILJA JJ, NIEMI M, NEUVONEN PJ: Rifampicin reduces plasma concentrations of celiprolol. Eur. J. Clin. Pharmacol. (2004) 59(11):819-824.
   PubMed Web of Science ®Google Scholar
• SCHMOLLING J, RENKE K, RICHTERO etal.: Digoxin, flecainide, and amiodarone transfer across the placenta and the effects of an elevated umbilical venous pressure on the transfer rate. Ther. Drug Monit. (2000) 22(5):582-588.
   PubMed Web of Science ®Google Scholar
• HALLAK M, NEERHOF MG, PERRY R, NAZIR M, HUHTA JC: Fetal supraventricular tachycardia and hydrops fetalis: combined intensive, direct, and transplacental therapy. Obstet. Gynecol. (1991) 78(3 Pt 2):523-525.
   PubMed Web of Science ®Google Scholar
• BARRILLEAUX PS, MARTIN JN Jr: Hypertension therapy during pregnancy. Clin. Obstet. Gynecol. (2002) 45(1):22-34.
   PubMed Web of Science ®Google Scholar
• WEINER CW, BUHIMSCHI C: Drugs for pregnant and lactating women. Churchill Livingstone, Philadelphia, US (2004):1101.
   Google Scholar
• WOLFF F, BREUKER KH, SCHLENSKER KH, BOLTE A: Prenatal diagnosis and therapy of fetal heart rate anomalies: with a contribution on the placental transfer of verapamil. J. Perinat. Med. (1980) 8(4):203-208.
   PubMed Web of Science ®Google Scholar
• SCHNEIDER H, PROEGLER M: Placental transfer of -adrenergic antagonists studied in an invitro perfusion system of human placental tissue. Am. J. Obstet. Gynecol. (1988) 159(1):42-47.
   PubMed Web of Science ®Google Scholar
• KOFAHL B, HENKE D, HETTENBACHA, MUTSCHLER E: Studies on placental transfer of celiprolol. Eur. J. Clin. Pharmacol. (1993) 44(4):381-382.
   PubMed Web of Science ®Google Scholar
• TIBERGHIEN F, LOOR F: Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anti-Cancer Drugs (1996) 7(5):568-578.
   PubMed Web of Science ®Google Scholar
• KAKUMOTO M, TAKARA K, SAKAEDAT etal.: MDR1-mediated interaction of digoxin with antiarrhythmic or antianginal drugs. Biol. Pharm. Bull. (2002) 25(12):1604-1607.
   PubMed Web of Science ®Google Scholar
• SINGH GK: Management of fetal tachyarrhythmias. Curr. Treat. Options Cardiovasc. Med. (2004) 6(5):399-406.
   PubMedGoogle Scholar
• MORRELL MJ: Antiepileptic drug use in women. In: Antiepileptic drugs (5th edition). R Levy, RH Mattson, BS Meldrum, EPerucca (Eds), Loppincott Williams and Wilkins, Philadelphia, US (2002):132-148.
   Google Scholar
• MYLLYNEN P, PIENIMAKI P, VAHAKANGAS K: Human placental perfusion method in the assessment of transplacental passage of antiepileptic drugs. Toxicol. Appl. Pharmacol. (2005) 207(2suppl):489-494.
   PubMedGoogle Scholar
• LINDHOUT D, OMTZIGT JG: Pregnancy and the risk of teratogenicity. Epilepsia (1992) 33(4):S41-S48.
   PubMed Web of Science ®Google Scholar
• LOSCHER W, POTSCHKA H: Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Nat. Rev. Neurosci. (2005) 76:22-76.
   Google Scholar
• GIBBS JP, ADEYEYE MC, YANG Z, SHEN DD: Valproic acid uptake by bovine brain microvessel endothelial cells: role of active efflux transport. Epilepsy Res. (2004) 58(1):53-66.
   PubMed Web of Science ®Google Scholar
• NIEBYL JR: Antidepressant drug use in pregnancy. J. Soc. Gynecol. Investig. (2005) 12(5):297.
   PubMedGoogle Scholar
• GENTILE S: The safety of newer antidepressants in pregnancy and breastfeeding. Drug Saf. (2005) 28(2):137-152.
   PubMed Web of Science ®Google Scholar
• CASPER RC, FLEISHER BE, LEE-ANCAJAS JC etal.: Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J. Pediatr. (2003) 142(4):402-408.
   PubMed Web of Science ®Google Scholar
• HEIKKINEN T, EKBLAD U, LAINE K: Transplacental transfer of amitriptyline and nortriptyline in isolated perfused human placenta. Psychopharmacology (2001) 153(4):450-454.
   PubMed Web of Science ®Google Scholar
• DORAN A, OBACH RS, SMITH BJ etal.: The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model. Drug Metab. Dispos. (2005) 33(1):165-174.
   PubMed Web of Science ®Google Scholar
• UHR M, GRAUER MT, HOLSBOER F: Differential enhancement of antidepressant penetration into the brain in mice with abcb1ab (mdr1ab) P-glycoprotein gene disruption. Biol. Psychiatry (2003) 54(8):840-846.
   PubMed Web of Science ®Google Scholar
• HEIKKINEN T, EKBLAD U, LAINE K: Transplacental transfer of citalopram, fluoxetine and their primary demethylated metabolites in isolated perfused human placenta. BJOG (2002) 109(9):1003-1008.
   PubMed Web of Science ®Google Scholar
• HEIKKINEN T, EKBLAD U, KERO P, EKBLAD S, LAINE K: Citalopram in pregnancy and lactation. Clin. Pharmacol. Ther. (2002) 72(2):184-191.
   PubMed Web of Science ®Google Scholar
• HENDRICK V, STOWE ZN, ALTSHULER LL etal.: Placental passage of antidepressant medications. Am. J. Psychiatry (2003) 160(5):993-996.
   PubMed Web of Science ®Google Scholar
• MORRISON JL, RURAK DW, CHIEN C etal.: Maternal fluoxetine infusion does not alter fetal endocrine and biophysical circadian rhythms in pregnant sheep. J. Soc. Gynecol. Invest. (2005) 12(5):356-364.
   PubMedGoogle Scholar
• CHAMA CM, AUDU BM, KYARI O: Prevention of mother-to-child transmission of HIV at Maiduguri, Nigeria. J. Obstet. Gynaecol. (2004) 24(3):266-269.
   PubMedGoogle Scholar
• SOBIESZCZYK ME, TALLEY AK, WILKIN T, HAMMER SM: Advances in antiretroviral therapy. Top. HIV Med. (2005) 13(1):24-44.
   PubMedGoogle Scholar
• CONNOR EM, SPERLING RS, GELBERR etal.: Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N. Engl. J. Med. (1994) 331(18):1173-1180.
   PubMed Web of Science ®Google Scholar
• OLIVERO OA, FERNANDEZ JJ, ANTIOCHOS BB etal.: Transplacental genotoxicity of combined antiretroviral nucleoside analogue therapy in Erythrocebus patas monkeys. J. Acquir. Immune Defic. Syndr. (2002) 29(4):323-329.
   PubMed Web of Science ®Google Scholar
• LORENZI P, SPICHER VM, LAUBEREAU B etal.: Antiretroviral therapies in pregnancy: maternal, fetal and neonatal effects. Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study. AIDS (1998) 12(18):F241-F247.
   PubMed Web of Science ®Google Scholar
• HUISMAN MT, SMIT JW, CROMMENTUYN KM etal.: Multi-drug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs. AIDS (2002) 16(17):2295-2301.
   PubMed Web of Science ®Google Scholar
• KIM RB, FROMM MF, WANDEL C etal.: The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-protease inhibitors. J. Clin. Invest. (1998) 101:289-294.
   PubMed Web of Science ®Google Scholar
• SCHUETZ JD, CONNELLY MC, SUND etal.: MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. (1999) 5(9):1048-1051.
   PubMed Web of Science ®Google Scholar
• COLLIER AC, KEELAN JA, VAN ZIJL PE etal.: Human placental glucuronidation and transport of 3azido-3-deoxythymidine and uridine diphosphate glucuronic acid. Drug Metab. Dispos. (2004) 32(8):813-820.
   PubMed Web of Science ®Google Scholar
• WANG X, FURUKAWA T, NITANDA T etal.: Breast cancer-resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol. Pharmacol. (2003) 63(1):65-72.
   PubMed Web of Science ®Google Scholar
• POIRIER MC, PATTERSON TA, SLIKKER W Jr, OLIVERO OA: Incorporation of 3-azido-3-deoxythymidine (AZT) into fetal DNA and fetal tissue distribution of drug after infusion of pregnant late-term rhesus macaques with a human-equivalent AZT dose. J. Acquir. Immune Defic. Syndr. (1999) 22(5):477-483.
   PubMed Web of Science ®Google Scholar
• BLANCHE S, TARDIEU M, RUSTIN P etal.: Persistent mitochondrial dysfunction and perinatal exposure to antiretroviral nucleoside analogues. Lancet (1999) 354(9184):1084-1089.
   PubMed Web of Science ®Google Scholar
• COLLIER AC, HELLIWELL RJ, KEELAN JA etal.: 3-Azido-3-deoxythymidine (AZT) induces apoptosis and alters metabolic enzyme activity in human placenta. Toxicol. Appl. Pharmacol. (2003) 192(2):164-173.
   PubMed Web of Science ®Google Scholar
• PACIFICI GM: Transfer of antivirals across the human placenta. Early Hum. Dev. (2005) 81:647-654.
   PubMed Web of Science ®Google Scholar
• MARZOLINI C, RUDIN C, DECOSTERD LA etal.: Transplacental passage of protease inhibitors at delivery. Swiss Mother + Child HIV Cohort Study. AIDS (2002) 16(6):889-893.
   PubMed Web of Science ®Google Scholar
• DOYLE LA, ROSS DD: Multi-drug resistance mediated by the breast cancer-resistance protein BCRP (ABCG2). Oncogene (2003) 22(47):7340-7358.
   PubMed Web of Science ®Google Scholar
• MOLSA M, HEIKKINEN T, HAKKOLAJ, HAKALA K etal.: Functional role of P-glycoprotein in the human bloodplacental barrier. Clin. Pharmacol. Ther. (2005) 78(2):123-131.
   PubMed Web of Science ®Google Scholar
• EICHELBAUM M, FROMM MF, SCHWAB M: Clinical aspects of the MDR1 (ABCB1) gene polymorphism. Ther. Drug Monit. (2004) 26(2):180-185.
   PubMed Web of Science ®Google Scholar
• FROMM MF: Importance of P-glycoprotein at bloodtissue barriers. Trends Pharmacol. Sci. (2004) 25(8):423-429.
   PubMed Web of Science ®Google Scholar
• SAKAEDA T, NAKAMURA T, OKUMURA K: Pharmacogenetics of drug transporters and its impact on the pharmacotherapy. Curr. Topics Med. Chem. (2004) 4:1383-1396.
   Google Scholar
• HOFFMEYER S, BURK O, VONRICHTER O etal.: Functional polymorphisms of the human multi-drug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity invivo. Proc. Natl Acad. Sci. USA (2000) 97(7):3473-3478.
   PubMed Web of Science ®Google Scholar
• VERSTUYFT C, SCHWAB M, SCHAEFFELER E etal.: Digoxin pharmacokinetics and MDR1 genetic polymorphisms. Eur. J. Clin. Pharmacol. (2003) 58(12):809-812.
   PubMed Web of Science ®Google Scholar
• SAITOH A, SINGH KK, POWELL CA etal.: An MDR1-3435 variant is associated with higher plasma nelfinavir levels and more rapid virologic response in HIV-1 infected children. AIDS (2005) 19(4):371-380.
   PubMed Web of Science ®Google Scholar
• ROBERTS RL, JOYCE PR, MULDER RT, BEGG EJ, KENNEDY MA: A common P-glycoprotein polymorphism is associated with nortriptyline-induced postural hypotension in patients treated for major depression. Pharmacogenomics J. (2002) 2(3):191-196.
   PubMedGoogle Scholar
• ITODA M, SAITO Y, KOMAMURA K etal.: Twelve novel single nucleotide polymorphisms in ABCB1/MDR1 among Japanese patients with ventricular tachycardia who were administered amiodarone. Drug Metab. Pharmacokinet. (2002) 17(6):566-571.
   PubMedGoogle Scholar
• TANABE M, IEIRI I, NAGATA N etal.: Expression of P-glycoprotein in human placenta: relation to genetic polymorphism of the multidrug resistance (MDR)-1 gene. J. Pharmacol. Exp. Ther. (2001) 297(3):1137-1143.
   PubMed Web of Science ®Google Scholar
• IMAI Y, NAKANE M, KAGE K etal.: C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance. Mol. Cancer Ther. (2002) 1(8):611-616.
   PubMed Web of Science ®Google Scholar
• ZAMBER CP, LAMBA JK, YASUDA K etal.: Natural allelic variants of breast cancer-resistance protein (BCRP) and their relationship to BCRP expression in human intestine. Pharmacogenetics (2003) 13(1):19-28.
   PubMedGoogle Scholar
• KOBAYASHI D, IEIRI I, HIROTA T etal.: Functional assessment of ABCG2 (BCRP) gene polymorphisms to protein expression in human placenta. Drug Metab. Dispos. (2005) 33(1):94-101.
   PubMed Web of Science ®Google Scholar
• LANG T, HITZL M, BURK O etal.: Genetic polymorphisms in the multi-drug resistance-associated protein 3 (ABCC3, MRP3) gene and relationship to its mRNA and protein expression in human liver. Pharmacogenetic (2004) 14(3):155-164.
   PubMedGoogle Scholar
• MEYER ZU SCHWABEDISSEN HE, JEDLITSCHKY G, GRATZ M etal.: Variable expression of MRP2 (ABCC2) in human placenta: influence of gestational age and cellular differentiation. Drug Metab. Dispos. (2005) 33(7):896-904.
   PubMed Web of Science ®Google Scholar